Protocol Details

Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number	05-HG-0131
Sponsoring Institute	National Human Genome Research Institute (NHGRI)
Recruitment Detail	Type: Participants currently recruited/enrolled Gender: Male & Female Min Age: 0 Max Age: 100
Referral Letter Required	No
Population Exclusion(s)	None
Special Instructions	Currently Not Provided
Keywords	Coronal Craniosynostosis; Pro250 Arg Mutation; Carpal Coalition; Tarsal Coalition; Hearing Loss
Recruitment Keyword(s)	Muenke Syndrome; Craniosynostosis
Condition(s)	Craniosynostosis; Muenke Syndrome
Investigational Drug(s)	None
Investigational Device(s)	None
Intervention(s)	None
Supporting Site	National Human Genome Research Institute

This study will explore the range and type of medical and developmental problems in patients with Muenke syndrome, a condition that results when one or more of the suture between the bones of the skull close before birth. Because of the premature closure, the skull is not able to grow in its natural shape; instead, it compensates with growth in areas of the skull where the sutures have not yet closed. This can result in an abnormally shaped head, wide-set eyes, and flattened cheekbones. Patients may also have an enlarged head, abnormalities of the hands or feet, and hearing loss.

The fibroblast growth factor receptor 3 (FGFR3) gene, which is involved in the development and maintenance of bone tissue, plays a role in Muenke syndrome. In some cases, the FGFR3 mutation is inherited from a parent with Muenke syndrome; in other cases, where there is no family history of the disorder, the mutation occurs anew. A better understanding of this gene may lead researchers to develop better treatments and genetic counseling for people affected by Muenke syndrome.

Patients with Muenke syndrome and their blood relatives may be eligible for this study. Family members with confirmed Muenke syndrome will have genetic counseling, and patients undergo the following tests and procedures:

-Review of medical records and test results.

-Questionnaires about the patient's prenatal, birth, newborn, and past medical history; family history; growth and development; medications; and current therapies.

-Physical, neurological, ear, nose and throat, dental, and eye examinations.

-Neuropsychological testing to assess cognitive thinking abilities.

-Hearing evaluation. This includes an audiology test in which the patients listens to soft tones through earphones; a power reflectance test in which a chirping sound is heard through an earpiece placed at the entrance to the ear canal, and possibly an ABR/ASSR test, in which electrodes are attached to the forehead, earlobes, and behind the ears to measure brain waves in response to certain conditions.

-MRI scan of the brain. MRI uses a strong magnetic field and radio waves to produce detailed pictures of the brain. During the scan, the patient lies on a table in a narrow cylinder (the scanner), wearing ear plugs to muffle loud noises that occur with electrical switching of the magnetic fields.

-MRI scan of the middle and inner ear. This test is similar to the MRI, but uses a dye injected in a vein to enhance the images.

-CT scan of the skull. CT uses x-rays to produce 3-dimensional images of the part of the body studied.

-Dental evaluation with x-rays.

-Skeletal survey (x-rays of all bones of the body).

-Developmental assessment of IQ testing.

-Blood tests for research purposes. A cell line may be established for use in future research.

-Medical photographs to demonstrate clinical features, including side and front views of the face, head, and other parts of the body that may be involved in Muenke syndrome, like the hands and feet.

-Other consultations or tests as clinically indicated

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Subjects who have had confirmation of a Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory. Our research team must receive a photocopy of the positive test result in order to enroll a patient in the study. All races and genders are known to be at risk for Muenke syndrome. Nationality or place of origin is not a specific barrier to participation.

Family members (typically parents or siblings) of probands with Muenke syndrome are also eligible to participate.

-Pediatric and adult individuals with physical examination findings consistent with Muenke syndrome, and adult individuals who are presumed to be unaffected based on examination findings will be given the option of enrolling in the research study for FGFR3 testing. Those individuals who are found to carry the Pro250Arg mutation may be invited to participate in the clinical and/or medical record review arms of the study.

- Clinically unaffected parents or adult siblings of a proband enrolled in the clinical protocol may choose to provide a blood sample. This sample will be used only for purposes of further research on Muenke syndrome.

Patient of interest cases. Geneticists and genetic counselors may refer individuals who are suspected to have Muenke syndrome, but who have not yet been tested for the FGFR3 Pro250Arg mutation. The purpose of enrolling these subjects is to evaluate a wider spectrum of patients for the mutation causing Muenke syndrome. Testing for the Pro250Arg mutation maybe performed at the discretion of our research group. Those individuals who are found to carry the Pro250 Arg mutation may be invited to participate in the clinical study arm and/or medical record review arm of the study. While we do not incomplete penetrance, children who are not eligible for enrollment due to lack of physical findings consistent with Muenke Syndrome will be referred for hearing testing, and further testing if indicated.

EXCLUSION CRITERIA:

Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors) or assent.

Protection of Vulnerable Populations

-In the process of recruiting individuals, we will use any of the following methods to evaluate a candidate for enrollment in the study:

-Review a brief clinical description from the referring physician,

-Interview a candidate by telephone, and/or

-Review a candidate's medical records.

We reserve the right to exclude individuals for whom the medical risks of travel and evaluation at NIH appear to outweigh the benefits of study participation.

We will not sponsor or encourage FGFR3 mutation testing of asymptomatic children. Family members below the age of 18 years who do not demonstrate physical examination findings consistent with Muenke syndrome will not be eligible for the study.

--Back to Top--

Citations:

Bellus GA, Gaudenz K, Zackai EH, Clarke LA, Szabo J, Francomano CA, Muenke M. Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet. 1996Oct;14(2):174-6.

Muenke M, Gripp KW, McDonald-McGinn DM, Gaudenz K, Whitaker LA, Bartlett SP, Markowitz RI, Robin NH, Nwokoro N, Mulvihill JJ, Losken HW, Mulliken JB, Guttmacher AE, Wilroy RS, Clarke LA, Hollway G, Ades LC, Haan EA, Mulley JC, Cohen MM Jr, Bellus GA, Francomano CA, Moloney DM, Wall SA, Wilkie AO, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet. 1997 Mar;60(3):555-64.

Moloney DM, Wall SA, Ashworth GJ, Oldridge M, Glass IA, Francomano CA, Muenke M, Wilkie AO. Prevalence of Pro250Arg mutation of fibroblast growth factor receptor 3 in coronal craniosynostosis. Lancet. 1997 Apr 12;349(9058):1059-62.

--Back to Top--

Contacts:

Principal Investigator	Referral Contact	For more information:
Maximilian Muenke, M.D. National Human Genome Research Institute (NHGRI) National Institutes of Health Building 35 Room 1B203 35 Convent Drive Bethesda, Maryland 20892 (301) 402-8167 mmuenke@nhgri.nih.gov	Maximilian Muenke, M.D. National Human Genome Research Institute (NHGRI) National Institutes of Health Building 35 Room 1B203 35 Convent Drive Bethesda, Maryland 20892 (301) 402-8167 mmuenke@nhgri.nih.gov	Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00106977

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

• Details on how to participate in a study
• Details on how to refer a patient to a study

NIH Clinical Studies Information Request

---

Contact the Office of Communications for:

• General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml

---

Contact the Department Clinical Research Informatics, (DCRI) for:

• Technical questions about Adobe Acrobat and the PDF format
• Technical questions about this web server

webmaster@cc.nih.gov